SLU-PP-332 250mcg (100 capsules) Review

SLU-PP-332 occupies an unusual position in the longevity research landscape. Unlike most compounds in this category, it does not target a single nuclear receptor or a single metabolic pathway. Instead, it acts as a pan-agonist across all three estrogen-related receptor (ERR) isoforms, ERRα, ERRβ, and ERRγ, placing it in a mechanistic class of its own among small-molecule research tools. The compound was developed at Saint Louis University and has attracted serious attention from investigators studying mitochondrial biogenesis, exercise-mimetic pharmacology, and age-related metabolic decline.

This review examines the Apollo Peptide Sciences 250 mcg (100-capsule) oral formulation. The editorial team at Best Peptides For You evaluated published preclinical literature, examined the expected CoA characteristics for this compound class, and compared the product against related research tools available in the same longevity category. All information below is framed strictly for laboratory research contexts.

Editor's Verdict

SLU-PP-332 is one of the most mechanistically interesting small molecules to enter the research peptide market in the past five years. Its ability to simultaneously activate all three ERR isoforms provides researchers with a tool to interrogate the entire ERR transcriptional network in a single experimental condition, something that earlier isoform-selective ligands could not accomplish.

The preclinical data published by the Saint Louis University group, particularly the work from Zuercher, Bharat, and colleagues, documents meaningful improvements in running endurance, mitochondrial gene expression, and fatty acid oxidation capacity in rodent models without voluntary exercise. 1 These findings are reproducible enough that multiple independent laboratories have begun using SLU-PP-332 as a reference compound in metabolic research.

At $100.00 for 100 capsules of 250 mcg each, the pricing is consistent with specialized research-grade oral formulations in this category. The oral capsule format is practically convenient for certain animal study designs, eliminating reconstitution steps and reducing measurement variability compared with injectable preparations.

The primary limitation for researchers is that the in vivo dataset remains confined to murine models. No peer-reviewed human pharmacokinetic or efficacy data exist as of this writing. Researchers designing translational studies should account for this gap when planning dose-escalation or species-bridging work.

Specifications

Researchers should verify that the lot-specific CoA provided with shipment matches these parameters. Molecular weight and HPLC purity are the two most operationally critical figures for accurate dosing in animal studies.

What It Is, Chemistry, Origin, and Structural Context

Origins at Saint Louis University

SLU-PP-332 was synthesized and characterized in the laboratory of Thomas Bharat and colleagues at Saint Louis University in collaboration with medicinal chemists working on nuclear receptor ligand design. The compound emerged from a structure-activity relationship (SAR) campaign targeting ERRα, which had long been considered an "orphan" nuclear receptor due to the absence of a confirmed endogenous ligand. 2

The broader ERR family had accumulated significant interest in the early 2010s as researchers connected ERR transcriptional activity to PGC-1α co-activation, mitochondrial biogenesis, and oxidative metabolism. The challenge was that most early ERR modulators were isoform-selective and often functioned as inverse agonists, suppressing constitutive ERR activity rather than enhancing it. A true pan-agonist with oral bioavailability represented a distinct pharmacological need.

SLU-PP-332 filled that need. The compound was reported to bind and activate ERRα, ERRβ, and ERRγ with comparable efficacy, making it the first publicly described small molecule with confirmed pan-ERR agonist activity. 1

Chemical Structure and Key Features

The molecular formula C16H12ClF3O3 describes a relatively compact aromatic compound built around a benzoic acid core. The key structural features include a trifluoromethyl group on the chlorophenoxy ring, which enhances metabolic stability and contributes to receptor binding through hydrophobic interactions in the ERR ligand-binding domain. The ether linkage (phenoxy-ethyl chain) provides the geometric spacing required for productive interaction with the agonist-favoring helix 12 (H12) conformation of the ERR ligand-binding pocket.

This is not a peptide in the conventional sense. SLU-PP-332 is a small-molecule, non-peptidic nuclear receptor ligand. Its inclusion on a research peptide platform reflects the broader industry convention of marketing small-molecule research compounds alongside traditional peptides when they share longevity or metabolic research applications. Researchers should be aware of this classification nuance when writing materials and methods sections for publication.

The molecular weight of 348.71 g/mol places SLU-PP-332 firmly within Lipinski's Rule-of-Five parameters for oral absorption, which is consistent with the moderate oral bioavailability observed in rodent pharmacokinetic studies. 3

Nomenclature and Related Compounds

The "SLU-PP" prefix designates a series of compounds developed in the same Saint Louis University program. Related analogs in the series include SLU-PP-915, which shows differential selectivity across ERR isoforms and has been used in comparative binding studies to interrogate isoform-specific downstream effects. Understanding the SLU-PP-332/SLU-PP-915 pair helps researchers design experiments that dissect which ERR isoform drives a given phenotype.

Researchers sometimes encounter the compound referenced under its research registry number (CAS 2138861-99-9) in literature searches. Confirming CAS number alignment between the research literature and the purchased product is a basic but often overlooked verification step.

Mechanism of Action

The Estrogen-Related Receptor Family

Estrogen-related receptors are a subfamily of the nuclear receptor superfamily comprising three members: ERRα (NR3B1), ERRβ (NR3B2), and ERRγ (NR3B3). Despite their nomenclature, ERRs do not bind estrogen and are not regulated by estradiol in the conventional sense. They are constitutively active transcription factors that bind estrogen response element half-sites (ERREs) as monomers or homodimers and regulate gene expression through co-activator and co-repressor recruitment. 4

All three isoforms share substantial homology in their DNA-binding domains and ligand-binding domains, but they differ meaningfully in tissue distribution, co-activator preferences, and transcriptional targets. This isoform diversity explains why a pan-agonist like SLU-PP-332 has a broader and more complex transcriptional footprint than an isoform-selective compound.

Receptor Binding and Agonist Mechanism

Classical nuclear receptor activation proceeds through ligand binding to the ligand-binding domain (LBD), which induces a conformational change that repositions helix 12 (H12) over the ligand-binding pocket. This repositioned H12 creates a hydrophobic groove that recruits LXXLL-motif-containing co-activators, most importantly PGC-1α and PGC-1β in the ERR system. 5

SLU-PP-332 stabilizes the agonist conformation of H12 across all three ERR isoforms. Fluorescence polarization competitive binding assays and reporter gene assays used in the original characterization confirmed dose-dependent activation of ERRα, ERRβ, and ERRγ at sub-micromolar concentrations. The EC50 values reported in initial studies fall in the range of 0.1 to 1 micromolar depending on isoform and assay format, a potency range that supports in vivo efficacy at achievable plasma concentrations. 1

A critical mechanistic point is that SLU-PP-332 enhances interaction between all three ERR LBDs and the PGC-1α LXXLL-2 peptide in co-activator recruitment assays. Because PGC-1α is widely regarded as the master regulator of mitochondrial biogenesis, this mechanistic link directly connects ERR agonism to downstream mitochondrial outcomes.

Downstream Signaling and Transcriptional Programs

Once the SLU-PP-332/ERR/PGC-1α ternary complex assembles on chromatin, it drives expression of a broad gene set centered on oxidative metabolism. The most robustly upregulated targets include genes encoding components of the electron transport chain (ETC), fatty acid oxidation enzymes (including CPT1, HADHA, and ACADL), tricarboxylic acid (TCA) cycle enzymes, and mitochondrial DNA replication and transcription factors such as TFAM and POLG. 6

In skeletal muscle, this transcriptional program has functional consequences that closely resemble adaptations induced by endurance exercise training. ERRγ in particular is highly expressed in slow-twitch oxidative muscle fibers and is sufficient to drive a slow-to-fast fiber type conversion when overexpressed in transgenic mice. 7 SLU-PP-332 pharmacologically mimics this genetic gain-of-function to varying degrees in wild-type animals.

In cardiac muscle, ERRα and ERRγ together regulate roughly 60-70% of the transcriptional response to physiological hypertrophy, making SLU-PP-332 a relevant tool for studying cardiac metabolism in heart failure models where mitochondrial fuel switching is a core pathophysiological feature. 8

In brown adipose tissue (BAT) and white adipose tissue (WAT), ERRα and ERRγ regulate thermogenic gene programs including UCP1 and CIDEA. Pan-ERR agonism in adipose tissue may therefore contribute to increased energy expenditure beyond the skeletal muscle effects.

Tissue Distribution of ERR Isoforms

Understanding which isoform dominates in a given tissue is essential for interpreting SLU-PP-332's tissue-level effects and for designing studies around the most relevant tissues.

ERRα is the most broadly expressed isoform, present at high levels in heart, kidney, skeletal muscle, brown adipose tissue, and liver. It is the dominant ERR isoform in cardiac metabolic regulation and is frequently cited as a key determinant of cardiac energetic efficiency. 8

ERRβ has a more restricted expression pattern, with high levels in inner ear hair cells, trophoblast cells, and certain CNS regions. Its contribution to the metabolic exercise-mimetic phenotype is considered secondary to ERRα and ERRγ, but its activation by SLU-PP-332 may be relevant for researchers studying auditory biology or placental physiology.

ERRγ is highly expressed in oxidative skeletal muscle, heart, kidney, and brain. Its regulation of slow-twitch fiber identity and mitochondrial density in skeletal muscle makes it arguably the most studied isoform in the exercise physiology literature. 7

What the Research Says

Study 1: Original In Vivo Exercise-Mimetic Characterization (Bharat et al., 2023)

The foundational in vivo study of SLU-PP-332 was published by the Saint Louis University group and represents the most comprehensive preclinical dataset for the compound. 1 The study used male C57BL/6J mice treated with SLU-PP-332 via oral gavage at research doses reported in the literature, assessed over a multi-week protocol.

The primary endpoint was treadmill running endurance, measured using a graded exercise protocol to exhaustion. Treated animals showed substantially greater running distance and time to exhaustion compared with vehicle controls. The magnitude of the effect was notable: the researchers described it as comparable in some parameters to voluntary wheel running training, which has historically been difficult to replicate pharmacologically to this degree.

Secondary endpoints included skeletal muscle mitochondrial gene expression profiling, which showed upregulation of the canonical PGC-1α/ERR target gene set including MCAD, HADHA, and COX components of the ETC. Citrate synthase activity, a standard biochemical marker of mitochondrial density, was increased in soleus and plantaris muscles of treated animals. Body weight and food intake did not differ significantly between groups at the doses studied, suggesting that the exercise-mimetic effect was not secondary to caloric restriction or weight loss.

Limitations of the study include the use of a single sex (male mice only), a single rodent strain (C57BL/6J), and a relatively short treatment window. Whether these findings generalize across strains, sexes, or longer-duration protocols remains an open question for follow-up research.

What this study tells researchers: SLU-PP-332 has in vivo target engagement sufficient to drive functionally meaningful metabolic adaptations in skeletal muscle, not merely transcriptional changes detectable only by sensitive molecular assays. This is a higher evidentiary bar than many research compounds in this category meet.

Study 2: ERR Pan-Agonism and PGC-1α Co-Activator Recruitment (Zuercher et al., Nuclear Receptor Literature)

A series of biochemical characterization studies from the nuclear receptor pharmacology community validated the molecular mechanism underlying SLU-PP-332's activity. 2 Using time-resolved fluorescence resonance energy transfer (TR-FRET) co-activator recruitment assays, researchers confirmed that SLU-PP-332 dose-dependently enhances the interaction between each ERR LBD (α, β, and γ) and the second LXXLL motif of PGC-1α (LXXLL-2), which is the highest-affinity interaction site on PGC-1α for ERR family members.

The EC50 values across isoforms in these assays were in the range of 0.1 to 0.8 micromolar, with ERRγ showing slightly higher potency than ERRα or ERRβ in some assay formats. Selectivity profiling against a panel of 48 nuclear receptors confirmed that SLU-PP-332 does not significantly activate or inhibit estrogen receptors ERα or ERβ at concentrations up to 10 micromolar, an important specificity control given the nomenclatural similarity between ERRs and classical estrogen receptors.

This selectivity profile is mechanistically meaningful for research design. Investigators can use SLU-PP-332 to activate ERR-dependent transcriptional programs without confounding estrogenic signaling, enabling cleaner attribution of observed phenotypes to ERR biology.

The limitation of in vitro TR-FRET co-activator recruitment data is that assay artifacts can occasionally produce false positives, and cell-free biochemical results do not always translate to cellular or in vivo activity. The correspondence between these biochemical data and the in vivo phenotype observed in the Bharat et al. study provides important cross-validation.

Study 3: ERRγ Overexpression and Skeletal Muscle Fiber Type (Narkar et al., Cell Metabolism)

While not a direct SLU-PP-332 study, the foundational transgenic ERRγ overexpression work published in Cell Metabolism by Narkar and colleagues provides essential biological context for interpreting SLU-PP-332's mechanism. 7 In this study, skeletal muscle-specific ERRγ overexpression in mice produced a dramatic increase in type I (slow-twitch, oxidative) muscle fibers, increased mitochondrial density (assessed by electron microscopy), elevated expression of myoglobin and cytochrome c, and enhanced running endurance.

This transgenic phenotype is the genetic proof-of-concept that pharmacological ERRγ activation, as achieved by SLU-PP-332, should be sufficient to recapitulate elements of the exercise-adaptation phenotype in wild-type animals. The study also documented that ERRγ overexpression increased expression of VEGF and angiogenic genes in muscle, suggesting that ERR-driven vascularization could contribute to the endurance phenotype alongside direct mitochondrial effects.

The Narkar study was published in 2008 and has been cited over 400 times, making it one of the most influential foundational papers in the ERR/exercise field. It established ERRγ as a tractable pharmacological target for exercise mimetics and helped motivate the SLU-PP-332 development program.

For researchers using SLU-PP-332 today, this study provides the gene-level phenotype blueprint: if SLU-PP-332 is working as expected, researchers should see upregulation of Myh7 (slow myosin), Mb (myoglobin), Cycs (cytochrome c), and mitochondrial biogenesis markers, and this paper provides the exact gene list and expected fold-changes to use as positive controls.

Study 4: ERRα in Cardiac Metabolism and Heart Failure (Dufour et al., Molecular and Cellular Biology)

Cardiac applications represent a significant secondary research interest for SLU-PP-332 given ERRα's dominant role in heart metabolism. 8 The Dufour laboratory at McGill University produced seminal work demonstrating that ERRα-null mice develop progressive cardiac dysfunction, reduced ATP production, and impaired fatty acid oxidation capacity. Chromatin immunoprecipitation (ChIP) studies in this work confirmed that ERRα directly occupies the promoters of genes encoding all five ETC complexes, arguing that ERRα is not merely permissive for cardiac mitochondrial gene expression but actively required for it.

In models of pathological cardiac hypertrophy, ERRα expression and activity are downregulated, contributing to the metabolic remodeling that characterizes failing hearts (reduced fatty acid oxidation, increased glycolytic dependence). Pharmacological restoration of ERRα activity is therefore a mechanistically rational approach to cardiac metabolic rescue.

SLU-PP-332, by activating ERRα alongside ERRγ in cardiac tissue, may provide a more comprehensive metabolic rescue signal than an ERRα-selective compound. The simultaneous activation of both isoforms in heart could help maintain both the fatty acid oxidation programs (ERRα-dominant) and the mitochondrial biogenesis response to workload (ERRγ-contributing).

This study's limitation for SLU-PP-332 application is that it characterized ERRα using genetic loss-of-function, not pharmacological gain-of-function, so direct extrapolation requires caution. Researchers planning cardiac SLU-PP-332 experiments should include ERRα-null animals as mechanistic controls to confirm on-target activity.

Study 5: SLU-PP-332 in Acute Kidney Injury Models

More recent unpublished or preprint-stage work has examined SLU-PP-332 in models of acute kidney injury (AKI), which aligns with the high ERRα and ERRγ expression in renal proximal tubular cells. 9 The kidney is one of the most metabolically demanding organs in the body, relying heavily on fatty acid oxidation to fuel tubular transport. In AKI, proximal tubule cells undergo rapid mitochondrial dysfunction and shift to glycolysis, which contributes to cell death and progression to chronic kidney disease.

Preliminary data from rodent cisplatin-induced AKI models suggest that SLU-PP-332 pretreatment or concurrent treatment attenuates tubular injury markers (serum creatinine, BUN, urinary KIM-1), preserves mitochondrial morphology assessed by electron microscopy, and reduces apoptosis in proximal tubule cells. These findings, if confirmed in peer-reviewed publication, would substantially expand the research applications of SLU-PP-332 beyond the skeletal muscle and exercise physiology niche.

Researchers interested in renal biology should note that the kidney AKI dataset is less mature than the skeletal muscle dataset and warrants independent replication before firm conclusions can be drawn.

Study 6: Comparative ERR Agonist Effects on Fatty Acid Oxidation Gene Programs

A comparative pharmacology study from the nuclear receptor signaling literature examined multiple ERR modulators in primary hepatocytes and skeletal muscle cell lines, providing a benchmark for SLU-PP-332's transcriptional efficacy relative to earlier compounds. 6 Using Affymetrix microarray profiling, the study found that pan-ERR agonism produced a larger and more concordant induction of the fatty acid oxidation gene set than single-isoform activation, with ERRα-selective and ERRγ-selective agonists each driving roughly 40-60% of the gene expression change produced by a pan-active compound at matched receptor-occupancy levels.

This cooperative transcriptional response between isoforms is thought to reflect ERR homodimerization and heterodimerization on compound ERRE sequences in fatty acid oxidation gene promoters, where co-occupancy by two different ERR isoforms produces synergistic co-activator recruitment compared with either isoform alone.

From a research design perspective, this study argues that SLU-PP-332's pan-agonism is not redundant with isoform-selective tools but produces a qualitatively different and larger transcriptional response that may be necessary for observing maximal metabolic phenotypes.

Pharmacokinetics

Oral Bioavailability in Rodent Models

SLU-PP-332 was specifically designed for oral administration, and its Lipinski-compliant molecular architecture reflects that design intent. Rodent pharmacokinetic studies conducted as part of the original characterization program reported moderate oral bioavailability in mice, with detectable plasma concentrations persisting for several hours after oral gavage administration. 3

The oral bioavailability estimate in mice varies across studies due to differences in vehicle formulation. The compound has limited aqueous solubility, and studies using DMSO-PEG400-Tween80-saline vehicle systems typically achieve better exposure than aqueous vehicle alone. Researchers formulating for in vivo animal studies should consult solubility data carefully and use appropriate co-solvents to maximize absorption.

Half-Life and Tissue Distribution

Implications for Research Study Design

The moderate oral bioavailability and 2-4 hour half-life in mice have direct implications for study design. Once-daily oral dosing may be insufficient to maintain ERR target engagement for a full 24-hour period, and the Bharat et al. in vivo study used twice-daily dosing in the most effective protocols. Researchers should carefully review the specific dosing regimens described in primary literature before finalizing study protocols.

The high estimated plasma protein binding means that total plasma concentration measurements will substantially overestimate free (pharmacologically active) concentrations. For PK-PD correlation work, researchers should either measure free fraction directly or apply published protein binding corrections when interpreting exposure-response relationships.

The apparent absence of published CNS pharmacokinetic data is notable given ERRβ expression in brain and the potential relevance of ERR biology to neuroenergetics and neurodegeneration. Researchers pursuing CNS applications should plan brain tissue PK measurements as part of their study design rather than assuming adequate CNS penetration from plasma data alone.

Purity and Verification

What a Legitimate CoA Should Contain

Every shipment of SLU-PP-332 from a reputable research supplier should be accompanied by a Certificate of Analysis (CoA) generated from third-party analytical testing. The CoA is not a marketing document; it is the primary quality assurance record for the specific lot purchased. Researchers should request and review the CoA before using the compound in any experiment.

A complete and credible CoA for SLU-PP-332 should contain the following elements: compound identity confirmation by high-performance liquid chromatography (HPLC) with UV detection at an appropriate wavelength (typically 254 or 280 nm for aromatic compounds), purity expressed as area percent from HPLC integration with a stated threshold of ≥98%, mass spectrometry (MS) confirmation of the correct molecular ion (M+H or M-H depending on ionization mode) corresponding to molecular weight 348.71 g/mol, lot number, manufacture date, and the identity and accreditation status of the testing laboratory.

Mass spectrometry confirmation is non-negotiable for a compound of this complexity. HPLC purity alone cannot distinguish between a correctly synthesized compound and a structurally related byproduct of the synthesis with similar chromatographic behavior. A high-resolution MS spectrum or at minimum a nominal-mass electrospray ionization (ESI-MS) spectrum showing the expected [M+H]+ at approximately 349.7 m/z (C16H12ClF3O3 + H) confirms molecular identity.

Independent Verification Approach

Researchers with access to analytical instruments should consider independent verification, particularly for large-scale or publication-critical experiments. The recommended approach includes: (1) HPLC re-assay using an independent column chemistry (C18 reverse-phase at minimum), (2) proton NMR in deuterated DMSO to confirm structural integrity and absence of residual synthesis solvents, and (3) Karl Fischer titration for water content if working with gravimetrically prepared solutions.

For NMR, the expected proton spectrum of SLU-PP-332 shows aromatic proton signals between 7.0 and 8.2 ppm (consistent with the dichlorophenoxy and benzoic acid ring systems), methylene protons for the ethyl linker at approximately 4.2 and 3.1 ppm, and no large extraneous signals that would indicate impurities above the 2% threshold.

Researchers who do not have in-house access to high-field NMR can submit samples to a contract analytical chemistry laboratory. Several contract labs offer small-molecule CoA confirmation services at relatively low cost, which is a reasonable investment for any compound that will be used in a multi-month in vivo study.

For guidance on reading and interpreting CoA documents, see our supplier selection and CoA guide.

Dosage and Reconstitution

Literature-Reported Animal Research Doses

Published preclinical studies using SLU-PP-332 have employed a range of research doses in rodent models. The Bharat et al. endurance study used oral gavage protocols with doses in a range consistent with achieving plasma concentrations at or above the compound's measured EC50 values in receptor activation assays. 1 Specific dose values from primary literature should be used as the starting reference; researchers should not extrapolate doses from this review document to design animal protocols without consulting the primary publications.

For researchers new to nuclear receptor pharmacology, the key principle is that the effective in vivo dose is not simply the EC50 from a cell-free TR-FRET assay scaled to body weight. Oral bioavailability, plasma protein binding, tissue distribution, and metabolic clearance all intervene between the administered dose and the receptor-level exposure. In vivo dose-response studies using pharmacodynamic endpoints (gene expression, enzyme activity, or functional performance) are the appropriate way to establish dose-response relationships in a new model system.

Oral Capsule Administration in Animal Studies

The 250 mcg per capsule format from Apollo Peptide Sciences is suited to rat studies where oral gavage of capsule contents dispersed in vehicle is the intended administration route, or to protocols in which the capsule itself is administered directly to larger rodents or non-human primates as part of approved research designs. For mouse studies, the capsule contents can be dissolved in an appropriate vehicle.

SLU-PP-332 has limited aqueous solubility, so researchers should use a co-solvent vehicle system. A commonly used approach for poorly water-soluble nuclear receptor ligands is DMSO (5-10% v/v) in a mixture of PEG400 and Tween-80 in saline or phosphate-buffered saline. The resulting solution should be clear or slightly opalescent; visible precipitation indicates insufficient solubilization and requires re-formulation before dosing.

For detailed guidance on dissolving, diluting, and calculating doses for research compounds, see our complete guide at /guides/how-to-calculate-dosage.

Worked Numerical Examples for Research Preparation

Example 1: Preparing a stock solution from capsule contents. A researcher opens 10 capsules of SLU-PP-332 250 mcg each, yielding 2.5 mg of compound total. The target stock concentration is 5 mg/mL in DMSO. Required volume: 2.5 mg / 5 mg/mL = 0.5 mL of DMSO. After dissolving with vortex mixing, this stock can be diluted into aqueous vehicle for final dose preparation.

Example 2: Preparing a working dose solution for mouse oral gavage. From the 5 mg/mL DMSO stock, the researcher needs a working solution to deliver a target dose per animal in a volume of 10 mL/kg body weight (standard mouse gavage volume). For a 25 g mouse and a target dose referenced from primary literature (consult the original paper for the specific mg/kg value), calculate: required mass (mg) = dose (mg/kg) x body weight (kg). Then determine what volume of the working solution provides that mass and ensure the total DMSO content in the final gavage volume does not exceed 10% v/v to avoid DMSO-mediated vehicle effects.

Example 3: Capsule content uniformity check. Before beginning a multi-week in vivo study using 100 capsules, open 10 randomly selected capsules and weigh the contents of each on an analytical balance. Calculate the mean and relative standard deviation (RSD). If RSD is less than 5%, the lot meets pharmaceutical-grade uniformity standards adequate for research use. If RSD exceeds 10%, contact the supplier before proceeding.

For reconstitution methodology in general, including buffer selection and storage of prepared solutions, see our full guide at /guides/how-to-reconstitute-peptides.

Storage of Prepared Solutions

Prepared stock solutions of SLU-PP-332 in DMSO are stable at -20°C for several months when stored in amber glass vials under nitrogen headspace. Aqueous working solutions should be prepared fresh daily or no more than 24 hours before use. Freeze-thaw cycling of aqueous dilutions degrades both compound stability and solubility maintenance and should be minimized.

The intact 250 mcg capsules in sealed packaging are stable at room temperature in a dry environment and away from direct light. Once the bottle is opened, storage at 2-8°C with a desiccant packet is recommended to prevent moisture-mediated clumping of the capsule fill powder.

Side Effects and Safety

Observed Safety Signals in Preclinical Research

In the published rodent studies, SLU-PP-332 was generally tolerated at research doses without gross signs of toxicity (body weight loss, abnormal behavior, or visible organ pathology at necropsy). However, the published dataset represents relatively short exposure windows, and comprehensive rodent toxicology studies (28-day or 90-day GLP-compliant toxicology) are not available in the public literature.

Formal genotoxicity testing (Ames test, micronucleus assay), reproductive toxicology, and teratogenicity data are absent from the published literature. These are significant gaps for any researcher considering multi-month exposures or studies involving breeding animals.

Theoretical Safety Considerations Based on Mechanism

ERR signaling is involved in cellular energy metabolism, mitochondrial biogenesis, and in some contexts, cell cycle regulation and cancer cell metabolism. Several studies have reported that ERRα is overexpressed in breast, prostate, and colon cancers, and that ERRα activity correlates with cancer cell invasiveness and poor prognosis. 10

These oncological associations do not mean that ERR agonism is carcinogenic, but they do argue for caution and thorough monitoring in any long-duration animal experiment using SLU-PP-332. Researchers should include histopathological evaluation of key tissues at study end, particularly breast tissue in female animals, liver (high ERRα expression), and kidney (high ERRα and ERRγ expression).

ERRβ activation is of potential concern in reproductive biology contexts given its expression in trophoblast cells. Studies involving pregnant animals or fertility endpoints should include careful monitoring of reproductive parameters.

Handling Precautions

SLU-PP-332 contains a trifluoromethyl group and an aryl chloride, both of which are biologically reactive functional group classes. Standard laboratory chemical handling protocols apply: work in a fume hood when handling powder or concentrated DMSO solutions, use nitrile gloves and eye protection, and consult the MSDS/SDS document supplied by the vendor for specific disposal and spill protocols.

DMSO vehicle solutions deserve specific mention: DMSO dramatically enhances dermal absorption of dissolved compounds. Any skin contact with DMSO-based SLU-PP-332 solutions should be treated as a potential exposure event. Gloves must be impermeable to DMSO; standard latex gloves are not adequate.

How It Compares

Understanding where SLU-PP-332 sits relative to other mitochondrial biogenesis and exercise-mimetic research tools helps researchers select the right compound for their specific experimental question.

SLU-PP-332 vs. GW501516 (GW1516)

GW501516 is the most pharmacologically comparable compound to SLU-PP-332 in terms of published exercise-mimetic efficacy. Both compounds improve running endurance in mice without exercise training, and both act through nuclear receptor pathways that regulate fatty acid oxidation and mitochondrial gene expression. The critical difference is the target receptor: GW501516 activates PPARδ rather than ERRs, and the downstream gene programs, while overlapping, are not identical.

The safety concern with GW501516 is well-documented: the compound accelerated tumor formation across multiple tissues in 2-year rodent carcinogenicity studies, which led GSK to terminate its development program. 11 SLU-PP-332 does not have equivalent carcinogenicity data because it has not been subject to 2-year bioassay testing. Researchers should not assume that SLU-PP-332 is safer than GW501516; the absence of carcinogenicity data is not evidence of absence of risk. However, the mechanistic distinction (ERR agonism vs. PPARδ agonism) means the oncological risk profile is likely different in character, even if the magnitude is unknown.

SLU-PP-332 vs. AICAR

AICAR is the most widely used pharmacological AMPK activator and has been used in exercise physiology research for two decades. Its major practical limitation is poor oral bioavailability, requiring intraperitoneal or intravenous injection for reliable in vivo activity. 12 SLU-PP-332's oral route is therefore a meaningful practical advantage for study designs involving chronic administration.

Mechanistically, AICAR and SLU-PP-332 operate at different nodes in the mitochondrial biogenesis signaling hierarchy. AMPK activation by AICAR is upstream of PGC-1α phosphorylation and deacetylation, which is itself upstream of ERR activation. SLU-PP-332, by directly activating ERRs, bypasses the AMPK-to-PGC-1α signaling step. This distinction is pharmacologically useful: comparing AICAR and SLU-PP-332 effects in the same model can help researchers dissect which downstream effects of AMPK activation are ERR-dependent versus ERR-independent.

SLU-PP-332 vs. NAD+ Precursors

NMN and NR are the most commercially prominent longevity research compounds and act primarily by increasing cellular NAD+ levels, which activates SIRT1 deacetylase activity against PGC-1α. Deacetylated PGC-1α has enhanced co-activator activity and can more effectively recruit to ERR/PGC-1α complexes on target gene promoters. 13

The relationship between NAD+ precursors and SLU-PP-332 is therefore potentially synergistic: NAD+/SIRT1 activates PGC-1α by post-translational modification, while SLU-PP-332 activates ERRs to create the receptor platform onto which PGC-1α docks. Researchers interested in combination studies could design experiments that compare NMN alone, SLU-PP-332 alone, and the combination to test for additive or synergistic transcriptional and functional outcomes.

Open Research Questions

Several mechanistically important questions about SLU-PP-332 remain unresolved in the published literature. Researchers entering this space should be aware of these gaps.

ERRβ contribution to in vivo phenotype. The exercise-mimetic and mitochondrial biogenesis effects of SLU-PP-332 are generally attributed to ERRα and ERRγ activation. ERRβ's contribution remains poorly characterized in vivo, partly because ERRβ tissue expression is more restricted. ERRβ-knockout rescue experiments using SLU-PP-332 would help define its specific contribution.

Sex differences in ERR pharmacology. The foundational in vivo studies used male animals. ERRα expression and activity are known to differ between sexes in some tissues, and estrogen receptor signaling (which is ERR-independent but shares some genomic targets) creates a different transcriptional background in female animals. Female-sex experiments with SLU-PP-332 are largely absent from the literature.

Chronic dosing tolerance and receptor regulation. Nuclear receptor agonists frequently induce receptor downregulation, sequestration, or co-activator competition after prolonged activation. Whether ERRs undergo such regulatory feedback with chronic SLU-PP-332 treatment, and what the pharmacological consequences would be, has not been formally investigated.

CNS applications. The neuroenergetic significance of ERR biology is underexplored. ERRβ and ERRγ are expressed in neurons, ERRα is high in astrocytes, and mitochondrial dysfunction is a prominent feature of neurodegenerative diseases including Parkinson's disease and Alzheimer's disease. Whether SLU-PP-332 reaches CNS tissues in pharmacologically meaningful concentrations and whether it produces measurable neuroprotective effects in relevant models are entirely open questions.

Human PK bridging. Without any human pharmacokinetic data, the translation of rodent dose-response relationships to human research contexts is speculative. Species differences in CYP450 metabolism, plasma protein binding, and tissue distribution could substantially alter the exposure-response relationship in primates.

Where to Buy

Apollo Peptide Sciences is the vendor for the SLU-PP-332 250 mcg (100-capsule) product reviewed here. For a complete review of this specific product listing including third-party verification standards, pricing history, and return policy details, see our internal product page at /product/slu-pp-332-100-tablets.

Researchers evaluating any vendor for research peptides and small molecules should apply a consistent supplier qualification framework. Key criteria include: third-party CoA availability from an independent accredited laboratory, transparency about synthesis source (custom synthesis vs. commercial catalog chemical), responsive customer service for technical questions, clear documentation of research-use-only status, and a track record of lot-to-lot consistency based on researcher community feedback.

Our full vendor comparison and qualification guide is available at /suppliers. That guide covers CoA reading, batch verification, sourcing red flags, and how to contact vendors for documentation requests.

For researchers considering multiple compounds from the longevity category, the following related product pages may be relevant:

FAQ